Morepen Labs Baddi facility clears USFDA inspection without any adverse observation
Gurugram: Morepen Labs has recently announced that the United States Food and Drug Administration (USFDA) has conducted an inspection of the API manufacturing facility, at Baddi, Himachal Pradesh, of the company."The facility has been cleared by USFDA on 24th March 2023 without any adverse observation (NIL 483)," the company stated in a BSE filing.Read also: Morepen Labs forms new...
Gurugram: Morepen Labs has recently announced that the United States Food and Drug Administration (USFDA) has conducted an inspection of the API manufacturing facility, at Baddi, Himachal Pradesh, of the company.
"The facility has been cleared by USFDA on 24th March 2023 without any adverse observation (NIL 483)," the company stated in a BSE filing.
Read also: Morepen Labs forms new subsidiary for medical devices
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd